Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 340


Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.

Mehta R, Katta H, Alimirah F, Patel R, Murillo G, Peng X, Muzzio M, Mehta RG.

PLoS One. 2013 Jun 10;8(6):e65113. doi: 10.1371/journal.pone.0065113.


A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer.

Suh YA, Kim JH, Sung MA, Boo HJ, Yun HJ, Lee SH, Lee HJ, Min HY, Suh YG, Kim KW, Lee HY.

Cancer Lett. 2013 May 10;332(1):102-9. doi: 10.1016/j.canlet.2013.01.022. Erratum in: Cancer Lett. 2013 Sep 28;338(2):328.


GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.

Yu T, Liu M, Luo H, Wu C, Tang X, Tang S, Hu P, Yan Y, Wang Z, Tu G.

J Steroid Biochem Mol Biol. 2014 Sep;143:392-403. doi: 10.1016/j.jsbmb.2014.05.003.


Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells.

Mehta RR, Katta H, Kalra A, Patel R, Gupta A, Alimirah F, Murillo G, Peng X, Unni A, Muzzio M, Mehta RG.

Clin Exp Metastasis. 2013 Oct;30(7):855-66. doi: 10.1007/s10585-013-9585-6.


Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.

Inoue S, Patil R, Portilla-Arias J, Ding H, Konda B, Espinoza A, Mongayt D, Markman JL, Elramsisy A, Phillips HW, Black KL, Holler E, Ljubimova JY.

PLoS One. 2012;7(2):e31070. doi: 10.1371/journal.pone.0031070.


Deguelin, an Akt inhibitor, down-regulates NF-κB signaling and induces apoptosis in colon cancer cells and inhibits tumor growth in mice.

Kang HW, Kim JM, Cha MY, Jung HC, Song IS, Kim JS.

Dig Dis Sci. 2012 Nov;57(11):2873-82. doi: 10.1007/s10620-012-2237-x.


Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway.

Murillo G, Peng X, Torres KE, Mehta RG.

Cancer Prev Res (Phila). 2009 Nov;2(11):942-50. doi: 10.1158/1940-6207.CAPR-08-0232.


Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.

Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM.

Breast Cancer Res. 2012 May 21;14(3):R79.


Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.

Liu T, Yacoub R, Taliaferro-Smith LD, Sun SY, Graham TR, Dolan R, Lobo C, Tighiouart M, Yang L, Adams A, O'Regan RM.

Mol Cancer Ther. 2011 Aug;10(8):1460-9. doi: 10.1158/1535-7163.MCT-10-0925.


Dipyridamole prevents triple-negative breast-cancer progression.

Spano D, Marshall JC, Marino N, De Martino D, Romano A, Scoppettuolo MN, Bello AM, Di Dato V, Navas L, De Vita G, Medaglia C, Steeg PS, Zollo M.

Clin Exp Metastasis. 2013 Jan;30(1):47-68. doi: 10.1007/s10585-012-9506-0.


Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.

Liu CY, Hu MH, Hsu CJ, Huang CT, Wang DS, Tsai WC, Chen YT, Lee CH, Chu PY, Hsu CC, Chen MH, Shiau CW, Tseng LM, Chen KF.

Oncotarget. 2016 Feb 23;7(8):9135-49. doi: 10.18632/oncotarget.7035.


Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway.

Li T, Zhang Q, Zhang J, Yang G, Shao Z, Luo J, Fan M, Ni C, Wu Z, Hu X.

BMC Cancer. 2014 Feb 16;14:96. doi: 10.1186/1471-2407-14-96.


Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.

Martin JL, de Silva HC, Lin MZ, Scott CD, Baxter RC.

Mol Cancer Ther. 2014 Feb;13(2):316-28. doi: 10.1158/1535-7163.MCT-13-0367.


Deguelin induces apoptosis by targeting both EGFR-Akt and IGF1R-Akt pathways in head and neck squamous cell cancer cell lines.

Baba Y, Fujii M, Maeda T, Suzuki A, Yuzawa S, Kato Y.

Biomed Res Int. 2015;2015:657179. doi: 10.1155/2015/657179.


Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer.

Arora R, Yates C, Gary BD, McClellan S, Tan M, Xi Y, Reed E, Piazza GA, Owen LB, Dean-Colomb W.

PLoS One. 2014 Jun 4;9(6):e98370. doi: 10.1371/journal.pone.0098370.


Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.

Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL.

J Clin Oncol. 2008 Feb 20;26(6):897-906. doi: 10.1200/JCO.2007.13.5939.

Items per page

Supplemental Content

Support Center